A Breath of Fresh Air in Asthma!
Asthma affects over 5 million people in the UK. Half a million of these have a severe form of the condition. Potentially life threatening attacks, known as exacerbations, are a frequent occurrence. Current treatment options to reduce the frequency of these exacerbations are limited.
For patients with allergic asthma, the immune system’s abnormal reaction to allergens is a major cause of asthma symptoms.
TLA is a treatment for patients with allergic asthma who, despite taking their asthma medications, still have poorly controlled asthma.
Allows the patient to sleep in clean air. Studies show TLA treatment can improve quality of life and asthma control in patients with allergic asthma
Can patients quality of life be improved?
222 participants will be invited to take part in the trial. 111 will receive an active TLA device and 111 will receive a placebo device which has been de-activated. Participants will be seen over a 12 month period to assess their asthma control and quality of life. Asthma attacks during the 12 month period will be reported to the trial team to see if the active treatment device is more effective at reducing the frequency of these attacks when compared to the placebo device. — Dr. Will Storrar
The LASER Trial - A breath of fresh air in Asthma!
The LASER Trial is funded by the National Institute for Health Research Health Technology Assessment Programme
(Project number 12/33/28)